3상모집 예정
A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02)
연구 개요
This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) in combination with bevacizumab works in treating platinum-sensitive ovarian cancer compared to standard treatments by checking whether it makes cancers smaller or disappear completely and if it helps participants live longer. The study also assesses whether Mo-Rez in combination with bevacizumab is safe and tolerated well by participants compared to standard treatments and aims to provide a better understanding of the main side effects of Mo-Rez.
- 스폰서
- 리드: GSK
- 적응증
- Ovarian Neoplasms
- 중재
- Mocertatug rezetecan (Mo-Rez), Carboplatin, Paclitaxel, Gemcitabine, Pegylated liposomal doxorubicin (PLD), Bevacizumab
- 목표 등록
- 690명
- 시작일
- 2026-09-22
- 완료(예정)
- 2033-04-22
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.